Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Gross Profit: 2011-2025

Historic Gross Profit for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to $29.0 million.

  • Iovance Biotherapeutics' Gross Profit rose 7.18% to $29.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 126.40%. This contributed to the annual value of $40.1 million for FY2024, which is 518.93% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Gross Profit stood at $29.0 million for Q3 2025, which was up 781.33% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Gross Profit peaked at $29.0 million during Q3 2025, and registered a low of -$6.5 million during Q1 2024.
  • Over the past 3 years, Iovance Biotherapeutics' median Gross Profit value was -$12,000 (recorded in 2023), while the average stood at $5.0 million.
  • Its Gross Profit has fluctuated over the past 5 years, first slumped by 210.08% in 2024, then skyrocketed by 1,354.96% in 2025.
  • Iovance Biotherapeutics' Gross Profit (Quarterly) stood at -$3.9 million in 2023, then soared by 232.84% to $5.2 million in 2024, then grew by 7.18% to $29.0 million in 2025.
  • Its Gross Profit was $29.0 million in Q3 2025, compared to $3.3 million in Q2 2025 and -$417,000 in Q1 2025.